Published in Ann Hematol on September 24, 2002
Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia (2006) 5.64
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (1997) 4.58
Primary cardiac lymphoma in immunocompetent patients: diagnostic and therapeutic management. Cancer (1997) 3.41
The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry. Hum Mol Genet (1996) 3.37
Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med (1988) 2.44
Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp Med (1995) 2.29
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol (2003) 2.16
Expression of DeltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ (2002) 2.14
A multicenter study of treatment of primary CNS lymphoma. Neurology (2002) 2.04
High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program. Diabetes (2001) 2.02
Takayasu's arteritis: A study of 104 Italian patients. Arthritis Rheum (2005) 1.94
Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology (1999) 1.88
Hypertension-associated point mutations in the adducin alpha and beta subunits affect actin cytoskeleton and ion transport. J Clin Invest (1996) 1.83
Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol (1999) 1.82
Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer (2007) 1.81
Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa. Ann Oncol (2006) 1.71
Comparison of tissue transglutaminase-specific antibody assays with established antibody measurements for coeliac disease. J Autoimmun (1999) 1.70
Capillary whole blood measurement of islet autoantibodies. Diabetes Care (1999) 1.66
Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol Today (1993) 1.64
Autoimmunity against pancreatic islets and other tissues before and after interferon-alpha therapy in patients with hepatitis C virus chronic infection. Diabetes Care (2000) 1.62
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) (2002) 1.61
Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med (1999) 1.58
The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood (2000) 1.58
Antibodies to tissue transglutaminase C in type I diabetes. Diabetologia (1999) 1.57
Thymoma associated with systemic lupus erythematosus and immunologic abnormalities. Lupus (2000) 1.53
Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol (1995) 1.53
Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol (2007) 1.47
Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology (2008) 1.44
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. Diabetes Obes Metab (2011) 1.38
PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum (2001) 1.37
Two single-nucleotide polymorphisms in the 5' and 3' ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus. Arthritis Rheum (2005) 1.37
Evidence by allelic association-dependent methods for a type 1 diabetes polygene (IDDM6) on chromosome 18q21. Hum Mol Genet (1997) 1.32
Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele. The IMDIAB Group. Nat Genet (1997) 1.31
Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology (2000) 1.28
Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report. Pediatrics (2001) 1.24
Endocrine responses of type 1 (insulin-dependent) diabetic patients following successful pancreas transplantation. Diabetologia (1983) 1.22
Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Ann Oncol (2004) 1.22
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer (2009) 1.20
Restriction endonuclease mapping of the root-inducing plasmid of Agrobacterium rhizogenes 1855. Plasmid (1983) 1.20
Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory context: role of opsonizing anti-beta2-glycoprotein I antibodies. Arthritis Rheum (1999) 1.19
Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes (1994) 1.19
Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res (2001) 1.18
Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum (1998) 1.17
Parameters associated with residual insulin secretion during the first year of disease in children and adolescents with Type 1 diabetes mellitus. Diabet Med (1998) 1.16
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes Metab (2009) 1.14
Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia (2012) 1.12
Plasmapheresis in the treatment of stiff-man syndrome. N Engl J Med (1989) 1.11
Meningeal involvement in Wegener's granulomatosis is associated with localized disease. Clin Exp Rheumatol (2006) 1.10
Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms. Cancer Res (1991) 1.08
Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes. Diabetes (2000) 1.07
The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. Ann Oncol (2013) 1.05
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. Ann Oncol (2007) 1.04
Lack of immunohistological changes in the islets of nondiabetic, autoimmune, polyendocrine patients with beta-selective GAD-specific islet cell antibodies. Diabetes (1994) 1.03
Autoantibodies in insulin-dependent diabetes recognize distinct cytoplasmic domains of the protein tyrosine phosphatase-like IA-2 autoantigen. J Immunol (1996) 1.03
Remnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity. Arthritis Rheum (2000) 1.03
Heterogeneity of autoantibodies in stiff-man syndrome. Ann Neurol (1993) 1.03
Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. Diabetologia (1996) 1.02
Evidence for a type 1 diabetes susceptibility locus (IDDM10) on human chromosome 10p11-q11. Hum Mol Genet (1997) 1.01
IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia (2005) 1.01
Prep1 (pKnox1)-deficiency leads to spontaneous tumor development in mice and accelerates EmuMyc lymphomagenesis: a tumor suppressor role for Prep1. Mol Oncol (2010) 1.00
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology (2006) 1.00
Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. J Intern Med (2004) 0.99
Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia (2011) 0.99
Non-surgical treatment with primary chemotherapy, with or without radiation therapy, of stage I-II high-grade gastric lymphoma. Leuk Lymphoma (1999) 0.99
Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. J Natl Cancer Inst (1996) 0.99
Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma. Ann Hematol (2009) 0.99
A combined evaluation of biochemical and morphological changes during human neuroblastoma cell differentiation. Cell Mol Neurobiol (1992) 0.98
Met signaling regulates growth, repopulating potential and basal cell-fate commitment of mammary luminal progenitors: implications for basal-like breast cancer. Oncogene (2012) 0.98
Dendritic cells preferentially internalize apoptotic cells opsonized by anti-beta2-glycoprotein I antibodies. J Autoimmun (1998) 0.98
Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol (1998) 0.98
Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia (2005) 0.98
Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity. Leukemia (2011) 0.98
Metabolic control of type I (insulin dependent) diabetes after pancreas transplantation. Br Med J (Clin Res Ed) (1985) 0.97
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer (2010) 0.97
Distinct cytoplasmic islet cell antibodies with different risks for type 1 (insulin-dependent) diabetes mellitus. Diabetologia (1992) 0.96
Prognostic significance of the histopathologic recognition of low- and high-grade components in stage I-II B-cell gastric lymphomas. Am J Surg Pathol (2001) 0.96
Translational mini-review series on immunology of vascular disease: mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol (2009) 0.95
Apoptotic cell clearance in systemic lupus erythematosus. II. Role of beta2-glycoprotein I. Arthritis Rheum (1998) 0.94
Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia (1998) 0.93
Primary brain CD30+ ALK1+ anaplastic large cell lymphoma ('ALKoma'): the first case with a combination of 'not common' variants. Ann Oncol (2002) 0.93
Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: antitumor effects. J Natl Cancer Inst (2000) 0.93
Sera from patients with IDDM and healthy individuals have antibodies to ICA69 on western blots but do not immunoprecipitate liquid phase antigen. J Autoimmun (1994) 0.92
Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci (2001) 0.92
Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol (2007) 0.92
Identification of CXCL13 as a new marker for follicular dendritic cell sarcoma. J Pathol (2008) 0.91
Autocrine regulation of volume-sensitive anion channels in airway epithelial cells by adenosine. J Biol Chem (1999) 0.91
Antibodies to recombinant human tissue-transglutaminase in coeliac disease: diagnostic effectiveness and decline pattern after gluten-free diet. Dig Liver Dis (2005) 0.91
Intravascular lymphomatosis (IL) in a child mimicking a posterior fossa tumor. J Neurooncol (2001) 0.90
Therapeutic management of stage I-II high-grade primary gastric lymphomas. Oncology (1999) 0.90
Daudi lymphoma killing triggers the programmed death of cytotoxic V gamma 9/V delta 2 T lymphocytes. J Immunol (1995) 0.90
Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. Blood (1996) 0.90
Inhibition of neuroblastoma-induced angiogenesis by fenretinide. Int J Cancer (2001) 0.89
Effects of gamma-interferon on the growth, morphology, and membrane and cytoskeletal proteins expression of Lan-1 cells. Exp Cell Res (1989) 0.89